Eugenol and isoeugenol, two components of clover oil, have been reported to possess several biomedical properties, such as anti-inflammatory, antimicrobial and antioxidant effects. This study aims to examine the anti-inflammatory effects of eugenol, isoeugenol and four of their derivatives on expression of inducible nitric oxide synthase (iNOS) activated by lipopolysaccharide (LPS) in mouse macrophages (RAW 264.7), and to investigate molecular mechanisms underlying these effects. We found that two derivatives, eugenolol and glyceryl-isoeugenol, had potent inhibitory effects on LPS-induced up regulation of nitrite levels, iNOS protein and iNOS mRNA. In addition, they both suppressed the release of tumor necrosis factor-a (TNF-a) and Interleukin-If (IL-l~) induced by LPS. Moreover, they both attenuated the DNA binding of NF-KB and AP-l, phosphorylation of inhibitory KBa (IKBa), and nuclear translocation of p65 protein induced by LPS. Finally, we demonstrated that glyceryl-isoeugenol suppressed the phosphorylation of ERKl/2, JNK and p38 MAPK, whereas eugenolol suppressed the phosphorylation of ERKl/2 and p38 MAPK. Taken together, these results suggest that that eugenolol and glyceryl-isoeugenol suppress LPS-induced iNOS expression by down-regulating NF-KB and AP-l through inhibition ofMAPKs and AktlIKBa signaling pathways. Thus, this study implies that eugenolol and glyceryl-isoeugenol may provide therapeutic benefits for inflammatory diseases.
NF-td3 is essential for LPS-mediated or inflammationmediated NO production (3) . Upstream to these transcriptional factors, signal transduction pathways including mitogen-activated protein kinases (MAPKs) and Akt also play important roles in the regulation of iNOS expression in the molecular mechanisms of inflammatory responses (4) .
Pharmacological options for the treatment of chronic inflammatory diseases are often associated with severe side effects due to prolonged duration of treatment. Therefore, developing compounds that are less toxic yet equally efficacious would have important clinical implications. Recently, there has been growing research interest in the synthesis of new anti-inflammatory compounds derived from eugenol and isoeugenol, two active components of clover oil, due to their antifungicidal, antibacterial, anti-oxidant and anti-inflammatory properties (5) (6) (7) (8) .
Previous studies have shown that several isoeugenolderived compounds, including dehydrodiisoeugenol, demethyldiisoeugenol, and o-diisoeugenol, have valuable cytoprotective and anti-inflammatory effects (5, (9) (10) (11) . We have also developed some novel derivatives, such as eugenolol, isoeugenolol and isoeugenodilol, and demonstrated their pleiotropic effects including vasodilatory, antioxidant, tracheal relaxant, and -or~-adrenoceptor blockade properties (12) (13) (14) . However, the anti-inflammatory effects of these novel derivatives have not yet been examined.
In this study, we used the mouse macrophage (RAW 246.7 cell) treated by lipopolysaccharide (LPS) as an in vitro model of inflammation. The anti-inflammatory effects of eugenol, isoeugenol and four associated derivatives ( Fig. lA) were examined by investigating their effects on LPS-induced production of inflammatory mediators (NO, TNF-a, IL-l B), protein expression of regulatory enzymes (iNOS), regulation oftranscriptional factors (NF-td3, CREB and AP-l), and related signal transduction (Akt and MAPKs).
MATERIALS AND METHODS

Materials
Eugenol and isoeugenol were purchased from Tokyo Kasei (Tokyo, Japan). Eugenolol, isoeugenolol, glycerylisoeugenol, and isoeugenodilol were synthesized in our laboratory as previously described (12) (13) (14) . Dulbecco's Modified Eagles Medium (DMEM) and fetal bovine serum (FBS) were purchased from GIBCO BRL Life Technologies (Grand Island, NY, USA). Penicillin, streptomycin, amphotericin B and glutamine were purchased from Kibbutz Beit Haemek (Israel). LPS from E. coli serotype 0127:B8, isopropanol, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MIT), N-(l-naphthyl-) ethylenediamide hydrochloride (NED), NaN0 2 , sulfanilamide,dimethylsulfoxide (DMSO), antibodies against~-actin and iNOS were purchased from Sigma-Aldrich Inc. (St. Louis, MO, USA). TNF-a and IL-I~ELISA assay kits were purchased from Pierce Biotechnology (Rockford, IL, USA). Antibodies against extracellular signal-regulated kinase (ERK), phospho-JNK and phospho-p38 MAPK were obtained from Upstate Biotechnology (Lake Placid, NY, USA). Antibodies against phospho-ERK, phospho-Akt, Akt, phospho-IKBa and IKBa were obtained from Cell Signaling Technology (Beverly, MA, USA).Antibodiesagainstp65 and PARPwere obtained from Millipore (Temecula, CA, USA).Antibody against p38 MAPK was obtained from Santa Cruz Biotechnology(Santa Cruz, CA, USA).
Cell culture
Macrophage RAW 264.7 cell line was purchased from the Bioresource Collection and Research Center in Taiwan. Cells were maintained in DMEM medium supplemented with 10% FBS, 2 mM glutamine, 100 Ulml of penicillin G, 100 ug/ml streptomycin and 0.25 mg/ml amphotericin B at 37°C and 5% COr All studies were performed with exponentially growing cells. Cells were seeded in cell culture plates or dishes initially. After 24 h, the cells were treated with various concentrations of derivatives and incubated for the indicated time. Finally, cells were scraped out and centrifuged at 13,000 rpm for 30 min at 4°C.
Cell viability assay
Cell viability was assessed by the MTT assay. The assay was performed according to the manufacturer's instructions. After experiments, MTT (0.5 mg/ml) was added in the medium for 4 h. Then the culture medium was removed, and cells were dissolved in isopropanol and shaken for 10 min. The amount of MTT formazan was quantified by determining the absorbance at 540 nm and 630 nm, using an ELISA reader (DYNEX Technologies, Germany). The viability was calculated as follows: Viability (%) = (ODs40,samPle-OD630,blank) I (OD S40 , control-OD630,blank)X 100.
Measurement afNO
The accumulation of nitrite, a metabolite of NO as an indirect indicator of NO production, was determined in the cell culture media by Griess reagent (I % sulfanilamide and 0.1% N-(l-naphthyl) ethylenediamide in 5% phosphoric acid). The culture supernatants were collected and mixed with an equal volume of Griess reagent and incubated at room temperature for 10 min. The absorbance was measured at 540 nm (OD S40 ) ' Measurement ofTNF-a and IL-lR AW 264.7 cells (l O' Iml) were seeded in the 24well plate. The cells were pretreated with various concentrations of eugenol and isoeugenol derivatives, followed by incubation with 100 ng/ml LPS for 24 h. Then the cell suspensions were collected, and the concentrations ofTNF-a and IL-l~were measured using enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's protocol.
Reverse-transcriptase polymerase chain reaction (RT-
res)
Total RNA was extracted with Trizol reagent by a standard protocol (Invitrogen, Carlsbad, Calif). Reverse transcription was performed with 5 ug mRNA and the random primer at 65°C for 5 min, then mixed with Moloney murine leukemia virus reverse transcriptase (RT) to react at 37°C for 1 h to obtain cDNA. Gene amplification was followed with RT-polymerase chain reaction (PCR). Primer sequences were as described: iNOS sense, 5'-CAGGAACCTACCAGCTCACTCT-3'; iNOS antisense, 5' -ACAAGATCAGGAGGGATTTCAA-3 '; GAPDH sense, 5'-AACTTTGGCATTGTGGAAGG-3'; and GAPDH antisense, 5'-CCCTGTTGCTGTAGCCGTAT-3'. Reaction cycles for iNOS and GAPDH included 30 cycles of 94°C for 30 s, 61.4°C for 30 s, nocfor 1 min, and a final incubation at noc for 7 min. Polymerase chain reaction products were analyzed on 1.5% agarose gel in the presence of 1 ug/ml of ethidium bromide.
Preparation ofcytosolic and nuclear protein extracts
Separation and preparation of cytoplasmic and nuclear extracts were performed using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce Biotechnology). In brief, RAW 264.7 cells (10 6 /ml) were harvested and resuspended in 100 ul of ice-cold cytoplasmic extraction reagent (CER) I containing protease inhibitor, and incubated on ice for 10 min. Then 5.5 ul of CER II was added to the cell suspension. After being vortexed for another 5 s, the cell extract was centrifuged at 4°C for 5 min at maximum speed, and the supernatant, which embraced the cytoplasmic fraction, was transferred to a fresh, pre-chilled tube and stored at -80°C. The pellet was resuspended in 50~l of ice-cold nuclear extraction reagent for 40 min. The insoluble fraction was precipitated by centrifugation at 4°C for 10 min at maximum speed, and the supernatant was used for nuclear fraction. The protein concentration was determined using the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA, USA). For subcellular location determination, the protein extracts were reacted with antibodies against lamin B (ProteinTech Group, Chicago, IL, USA), the nuclear marker, and~-actin, the cytoplasmic marker, respectively.
Western blot analysis
Cells were treated with various concentrations of eugenol and isoeugenol derivatives for the indicated time. Reactions were terminated by washing twice with cold PBS. The cells were then harvested and Western blot analyses were performed as we previously described (15) .
Electrophoretic mobility shift assay (EMSA)
The protein content of the nuclear extracts of RAW 264.7 cells was determined using a Bio-Rad Protein Assay kit according to the manufacturer's instructions. The sequences of the double-stranded oligonucleotides used to detect the DNA-binding activities of NF-KB, AP-l and CREB are as follows: NF-KB, 5'-GATC TCAGAGGGGACTTTCCGAGAGA-3'; AP-l, 5'-CGCTTGATGAGTCAGCCGGAA-3', and CREB, 5' -AGAGATTGCCTGACGTCAGAGAGCTAG-3'. The double-stranded oligonucleotides were end-labeled with 3' -biotin. EMSA was performed using Lightshift" Chemiluminescent EMSA kit (Pierce Biotechnology), and the procedure was performed according to the manufacturer's instructions. Nuclear proteins (l 0 ug) were incubated with IX binding buffer, 50 ng/ul poly (dl-dC), 2.50% glycerol, 0.05% NP-40, and 5 mM MgCl 2 on ice for 20 min. 20 finol biotin-labeled DNA was then added and mixed for another 20 min. The reaction mixture was analyzed using 8% non-denaturing polyacrylamide gel. The protein-DNA-biotin complexes were blotted onto Nylon membrane followed by UV cross-linking. The complexes were revealed with blocking buffer, horseradish peroxidase-conjugated streptavidin, substract equibilium buffer, and then exposed to X-ray film.
Statistical analysis
The results are expressed as mean ± SEM. Statistical differences were estimated by one-way analysis of variance (ANOVA)followed by Dunnett's test. Ap value < 0.05 was considered significant.
RESULTS
Effects of eugenol, isoeugenol and their derivatives on cell viability
Cytotoxic effects of eugenol, isoeugenol and four associated derivatives (eugenolol, isoeugenolol, 
Effects of eugenol, isoeugenol and their derivatives on NO production, iNOS protein and mos mRNA expression
A series of experiments was performed to compare effects of these derivatives on the NO pathway in RAW 264.7 cells treated with LPS. We first found that eugenolol and glyceryl-isoeugenol had more potent inhibitory effects on LPS-induced NO production than others ( Fig. 2A) and 7.9 11M, respectively, while the IC so values of eugenol and isoeugenol were 1250 11M and 20.3 11M, respectively. Likewise, eugenolol and glycerylisoeugenol decreased iNOS mRNA expression by 50% and 48%, respectively (Fig. 2B) .
Effects of eugenol, isoeugenol and their derivati ves on TNF-a and IL-IP?
As shown in Fig. 3 , LPS stimulated significant production of TNF-a (3356±93 pg/ml) and IL-IP (l29±9 pg/ml). We found that eugenolol and glyceryl- 
Effects of eugenol, isoeugenol and their derivatives on DNA binding activities of NF-KB, AP-l and CREB
It is known that NF-KB activation is important for the expression of iNOS induced by LPS. Pretreatment with eugenolol or glyceryl-isoeugenol significantly attenuated LPS-induced NF-KB DNA binding activity (Fig. 4A) . We further determined whether these derivatives also affected other transcription factors and found that DNA binding activity of AP-I and CREB were activated by LPS (Fig. 4, B and C) . In addition, pretreatment with eugenolol or glyceryl-isoeugenol attenuated LPSinduced activation ofAP-l, but not CREB.
Effects of eugenol, isoeugenol and their derivatives on NF-KB activation
We further determined the effects on LPS-induced nuclear translocation of p65, a major component of NF-KB. As shown in Fig. 5, A and B, pretreatment with eugenolol or glyceryl-isoeugenol significantly decreased LPS-induced expressions of p65 in the nucleus. Translocation of NF -KB to the nucleus is preceded by proteolytic degradation of IKBa subunit. To investigate whether these derivatives could affect IKBa, we found that LPS down-regulated the IKBa expression ( Fig. 5A) ; however, both eugenolol and glyceryl-isoeugenol preserved its expression. Since phosphorylation ofIKBa precedes degradation ofIKBa, we further determined effects of these derivatives on IKBa phosphorylation and found that both eugenolol and glyceryl-isoeugenol inhibited LPS-induced IKBa phosphorylation (Fig. 5, A and C) .
Effects of eugenol, isoeugenol and their derivatives on phosphorylation ofMAPKs and Akt
To investigate whether the inhibition of iNOS by these derivatives is mediated through modulation of MAPKs pathway, we further examined effects on phosphorylation ofERK, JNK, and p38 MAPK. We found that LPS induced phosphorylation ofMAPKs, and these effects were inhibited by pretreatment with .. .. glyceryl-isoeugenol ( Fig. 6 ). In addition, eugenolol attenuated LPS-induced phosphorylation of ERK and p38 MAPK, but not JNK (Fig. 6) .
It has been shown that transcriptional activation of NF-KB can be regulated through Akt signaling pathway (16) . To further clarify whether Akt plays a role in the upstream signaling ofNF-KB inactivation, the effects of these derivatives on LPS-induced Akt activation were examined. Our results showed that pretreatment with 50 11M eugenolol or glycerylisoeugenol significantly reduced the LPS-elicited Akt phosphorylation (Fig. 7) .
I~II
NO release, as well as TNF-a and IL-l~production in RAW 264.7 cells activated by LPS. In addition, our findings suggest that these anti-inflammatory effects are potentially mediated by inhibitions of MAPKs and Akt/hcBa signaling pathways with associated down-regulations of NF-KB and AP-l. Thus, the present study provides the novel evidence of anti-inflammatory properties and mechanisms of eugenolol and glyceryl-isoeugenol.
TNF-c and IL-l~are important pro-inflammatory cytokines that mediate inflammatory responses in vitro and in vivo (19) . Hence, after determining effects of these derivatives on the NO pathway, we further examined the effects of eugenolol and glyceryl-isoeugenol on TNF-a and IL-l~production, and found that they both significantly inhibited the release of TNF-a and IL-l~, indicating that these suppressive effects on pro-inflammatory cytokines were in parallel with their inhibitory effects on NO production.
Transcriptional factors NF-KB and AP-l are both important regulators of LPS-mediated iNOS expression in macrophages (20) . We therefore investigated the effects on transcriptional factors and found that eugenolol and glyceryl-isoeugenol inhibited DNA binding activity of NF-KB and AP-l. In the cytoplasm, NF-KB is bound tightly to its inhibitory subunit IKBa, so we further determined the effects of eugenolol and glycerylisoeugenol on degradation and phosphorylation of IKBa and the nuclear translocation of activated NF-KB. Our findings suggest that eugenolol and glyceryl-isoeugenol may inhibit NF-KB activation by suppressing both phosphorylation of IKBa and nuclear translocation of the p65 subunit of NF-KB. Given that Akt is an important upstream signaling pathway for NF-KB activation, our study further showed that eugenolol and glyceryl-isoeugenol significantly decreased phosphorylation of Akt, supporting the notion that inhibition ofthe Akt/IKBa/ NF-KB pathway mediates the anti-inflammatory actions of these two derivatives.
Mounting evidence indicates that MAPKs including ERK1I2, JNK and p38 MAPK have critical roles in the signaling ofpro-inflammatory mediators. For example, LPS-induced TNF-a production in macrophages and monocytes is dependent on the activation ofthe MAPKs family (21) (22) . In addition, Fig. 7 . Effects on LPS-induced phosphorylation of Akt. Cells were pretreated with 10 and 50~M ofthese derivatives for 30 min followed by incubation with LPS (100 ng/ml) for 30 min. Each value represents the mean ± SEM ofthree independent experiments, with triplicate determinations in each experiment. ## p<O. 0I compared with the control ; *p<0.05, **p<O.OI compared with LPS alone.
Excessive NO production is associated with various serious diseases such as septic shock, stroke and chronic inflammatory disease (17) (18) . Understanding regulatory mechanisms of NO in the LPS-stimulated cell model may provide insights into novel therapeutic strategy for inflammatory diseases.
In this study, we demonstrated that eugenolol and glyceryl-isoeugenol attenuated iNOS expression and recent studies have shown the participation of p38 MAPK in the activation of NF-KB in macrophages (23) , and the involvement of ERKl/2 and JNK in the LPS-activated iNOS expression in RAW 264.7 cells (24) . Thus, we further investigated the effects of eugenolol and glyceryl-isoeugenol on MAPKs and found that eugenolol attenuated the LPS-induced phosphorylation of ERK and p38 MAPK, but not JNK. In addition, glyceryl-isoeugenol attenuated LPS-induced phosphorylations of ERK, JNK, and p38 MAPK. These findings suggest that eugenolol and glyceryl-isoeugenol may attenuate activations of iNOS, TNF-a and NF-KB in macrophages by inhibition of the MAPKs signaling pathway.
In conclusion, this study demonstrates that eugenolol and glyceryl-isoeugenol may suppress LPS-mediated iNOS expression and proinflammatory cytokines by down-regulating NF-KB and AP-I, through inhibition of MAPKs and Akt/ IKBa signaling pathways. Our findings provide the molecular basis for the anti-inflammatory properties of eugenolol and glyceryl-isoeugenol, and imply their potential therapeutic roles in the management of inflammatory diseases.
